IGX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

IntelGenx Technologies Insider Trading History Chart

IntelGenx Technologies Share Price & Price History

C^$0.58

▲ +0.01 (1.75%)

As of 10/7/2021 12:59 AM ET

Days: 30 | 90 | 365

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

IntelGenx Technologies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/30/2022	Horst G. Zerbe	Director	Buy	14,000	C$0.17	C$2,380.00	368,064
9/29/2022	André Godin	Senior Officer	Buy	5,000	C$0.17	C$850.00	308,399
9/27/2022	André Godin	Senior Officer	Buy	1,000	C$0.18	C$180.00	294,399
9/22/2022	Tommy Kenny	Director	Buy	23,500	C$0.20	C$4,582.50	109,500
9/21/2022	André Godin	Senior Officer	Buy	20,000	C$0.18	C$3,600.00	293,399
3/30/2022	Dana Matzen	Senior Officer	Buy	25,000	C$0.33	C$8,280.00	50,000

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for IntelGenx Technologies (CVE:IGX)

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Today's Range

Now: C$0.58

C$0.58

C$0.60

50 Day Range

MA: C$0.58

C$0.58

52 Week Range

Now: C$0.58

C$0.17

C$0.85

Volume

11,848 shs

Average Volume

56,279 shs

Market Capitalization

C$87.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of IntelGenx Technologies?: IntelGenx Technologies' top insider shareholders include:
Horst G Zerbe (Director)
André Godin (Senior Officer)
Tommy Kenny (Director)
Learn More about top insider investors at IntelGenx Technologies.